Condition
Diabetes Mellitus, Type 2
Locations
Croatia, Poland, Portugal, Slovakia, South Korea, Spain, Thailand, United States
Start date
17/04/2026
Identifiers
Trial ID NN9662-8160,
NCT number NCT07415954,
Eudract number Not Available
NCT number NCT07415954,
Eudract number Not Available
Summary
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Trial Overview:
Treatment
DRUG: NNC0662-0419
DRUG: Semaglutide
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Apr 17 2026 - Oct 01 2027
Participants
270
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.